Pharmidex team are proud to present it's latest involvement on the recent publication on African Typanosomiasis
Pharmidex are proud to be part of the recent publication on African Trypanosomiasis in Journal of Antimicrobial Agents
Pharmidex are proud to be part of the recent publication on African Trypanosomiasis in Journal of Antimicrobial Agents
The Pharmidex team are proud to present it's latest involvement on the recent publication on African Typanosomiasis which was published in the International journal of antimicrobial agents. Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis - International Journal of Antimicrobial Agents Human African trypanosomiasis (HAT) is a neglected tropical disease, with a population of 70 million at risk. Current treatment options are limited.
In the search for new therapeutics, the repurposing of the broad-spectrum antiprotozoal drug fexinidazole has completed Phase III trials with the anticipation that it will be the first oral treatment for HAT.
For more information please see -
https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents
